Multicenter evaluation of the NeuMoDx™ SARS-CoV-2 Test

Area of Science:

• * Molecular diagnostics
• * Virology
• * Public health

Background:

• * The COVID-19 pandemic caused by SARS-CoV-2 has led to a global health crisis.
• * Social distancing measures are insufficient alone, necessitating early diagnosis and contact tracing.
• * High-throughput diagnostic assays are critical for managing disease spread and resuming social activities.

Purpose of the Study:

• * To evaluate the analytical and clinical performance of the NeuMoDx™ SARS-CoV-2 assay.
• * To assess the suitability of the NeuMoDx molecular system for high-throughput COVID-19 testing.
• * To provide performance data from multiple independent testing centers.

Main Methods:

• * The NeuMoDx™ SARS-CoV-2 assay is a fully automated, qualitative real-time RT-PCR test.
• * Performed on the NeuMoDx molecular system, it offers a throughput of up to 288 tests per 8-hour shift.
• * Analytical and clinical performance was assessed at three major healthcare institutions.

Main Results:

• * The NeuMoDx™ SARS-CoV-2 assay demonstrated reliable performance in diagnostic settings.
• * The automated system facilitates high-throughput testing, meeting demands for large-scale screening.
• * The assay received emergency use authorization from the FDA, indicating its clinical utility.

Conclusions:

• * The NeuMoDx™ SARS-CoV-2 assay is a valuable tool for rapid and accurate COVID-19 diagnosis.
• * Its high throughput and automation support effective public health strategies for pandemic control.
• * The assay's performance across multiple centers validates its use in diverse clinical environments.